Analyst downgrades and guidance reset put Inspire Medical Systems in focus
Inspire Medical Systems (INSP) is back on investor radars after analysts sharply cut revenue and earnings forecasts, following a first quarter shift from profit to net loss and a reduction in 2026 guidance.
See our latest analysis for Inspire Medical Systems.
The recent guidance reset and first quarter loss have coincided with weaker trading, with the share price down 18.44% over 30 days and the 1-year total shareholder return down 72.42%. This reflects fading momentum as investors reassess future prospects.
If this shift in sentiment has you reconsidering healthcare exposure, it may be worth widening your search to other medical technology names using our screener for 33 healthcare AI stocks.
With the stock down sharply over 1 and 3 years and trading below both analyst targets and some intrinsic value estimates, the key question is whether this reset is creating a genuine opportunity or if markets already see limited future growth.
Most Popular Narrative: 44.5% Undervalued
The most followed narrative pegs Inspire Medical Systems' fair value at $79.42 versus the last close of $44.06, framing the recent share price slide as a potential disconnect with modelled long term earnings power under a 7.7% discount rate.
The recent delay in transitioning centers to the Inspire V next-generation system, including slower onboarding, delayed SleepSync implementation, and the Medicare billing update, are transitory issues; as these barriers resolve (with Medicare billing now live and most centers expected to complete onboarding by end of Q3), procedure volumes and revenue growth are positioned to reaccelerate in 2026 as pent up demand is realized.
Curious how a slower near term revenue path, lower future margins and a reset earnings base can still support a higher fair value than today. The narrative leans on specific revenue run rate assumptions, a lower but still premium earnings multiple and detailed reimbursement expectations to bridge that gap.
Based on this narrative, analysts anchor on a fair value of $79.42 for Inspire Medical Systems, which implies the shares trade at a 44.5% discount to that estimate, even though revenue growth and earnings are expected to soften from prior models.
Result: Fair Value of $79.42 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the story can change quickly if Inspire V rollout issues persist, or if reimbursement decisions and physician fee clarity move against current analyst assumptions.
Find out about the key risks to this Inspire Medical Systems narrative.
Next Steps
With sentiment split between concern and optimism, it makes sense to review the data yourself and move quickly while information is fresh; to see how those risks and potential rewards stack up side by side, take a closer look at the 4 key rewards and 1 important warning sign.
Looking for more investment ideas?
Do not stop at one stock. Use data driven tools to quickly compare different opportunities and keep your watchlist working harder for you.
- Spot potential value opportunities early by scanning companies that may trade below their fundamentals using the 44 high quality undervalued stocks.
- Prioritize financial strength by screening for companies with robust balance sheets and steady fundamentals through the solid balance sheet and fundamentals stocks screener (46 results).
- Hunt for underfollowed opportunities by filtering for lesser known companies with strong underlying metrics in the screener containing 22 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com